-
1
-
-
80051549633
-
Ovarian cancer
-
Hong W.K. Bast R.C. Jr, Hait W. et al, eds. Shelton CT: People's Medical Publishing House-USA.
-
Berek JS, Friedlander ML, Bast RC Jr,. Ovarian cancer. In:, Hong WK, Bast RC Jr, Hait W, et al, eds. Holland-Frei Cancer Medicine. 8th ed. American Association for Cancer Research. Shelton CT: People's Medical Publishing House-USA; 2010: 1344-1375.
-
(2010)
Holland-Frei Cancer Medicine. 8th Ed. American Association for Cancer Research
, pp. 1344-1375
-
-
Berek, J.S.1
Friedlander, M.L.2
Bast, Jr.R.C.3
-
2
-
-
67650874081
-
Cancer statistics, 2009
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
-
(2009)
CA Cancer J Clin.
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
3
-
-
67649440886
-
The biology of ovarian cancer: New opportunities for translation
-
Bast RC Jr, Hennessy B, Mills GB,. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9: 415-428.
-
(2009)
Nat Rev Cancer.
, vol.9
, pp. 415-428
-
-
Bast, Jr.R.C.1
Hennessy, B.2
Mills, G.B.3
-
4
-
-
33644846509
-
Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction?
-
DOI 10.1038/nrc1799, PII N1799
-
Baylin SB, Ohm JE,. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006; 6: 107-116. (Pubitemid 43361543)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.2
, pp. 107-116
-
-
Baylin, S.B.1
Ohm, J.E.2
-
5
-
-
0036274359
-
The fundamental role of epigenetic events in cancer
-
Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415-428. (Pubitemid 34587077)
-
(2002)
Nature Reviews Genetics
, vol.3
, Issue.6
, pp. 415-428
-
-
Jones, P.A.1
Baylin, S.B.2
-
6
-
-
34250213859
-
DNA methylation as a therapeutic target in cancer
-
Issa JP,. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007; 13: 1634-1637.
-
(2007)
Clin Cancer Res.
, vol.13
, pp. 1634-1637
-
-
Issa, J.P.1
-
7
-
-
74949095984
-
Decitabine in the treatment of myelodysplastic syndrome
-
Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F,. Decitabine in the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther. 2010; 10: 9-22.
-
(2010)
Expert Rev Anticancer Ther.
, vol.10
, pp. 9-22
-
-
Santos, F.P.1
Kantarjian, H.2
Garcia-Manero, G.3
Issa, J.P.4
Ravandi, F.5
-
8
-
-
80052922810
-
A phase IB-IIA study to reverse platinum resistance by use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian
-
In press.
-
Fu S, Hu W, Iyer R, et al. A phase IB-IIA study to reverse platinum resistance by use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian Cancer. In press.
-
Cancer.
-
-
Fu, S.1
Hu, W.2
Iyer, R.3
-
9
-
-
36048958965
-
Histone deacetylase inhibitors: Overview and perspectives
-
DOI 10.1158/1541-7786.MCR-07-0324
-
Dokmanovic M, Clarke C, Marks PA,. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007; 5: 981-989. (Pubitemid 350080267)
-
(2007)
Molecular Cancer Research
, vol.5
, Issue.10
, pp. 981-989
-
-
Dokmanovic, M.1
Clarke, C.2
Marks, P.A.3
-
10
-
-
33644814867
-
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action
-
Zhang C, Richon V, Ni X, Talpur R, Duvic M,. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005; 125: 1045-1052.
-
(2005)
J Invest Dermatol.
, vol.125
, pp. 1045-1052
-
-
Zhang, C.1
Richon, V.2
Ni, X.3
Talpur, R.4
Duvic, M.5
-
11
-
-
43049091153
-
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
-
Modesitt SC, Sill M, Hoffman JS, Bender DP,. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 109: 182-186.
-
(2008)
Gynecol Oncol.
, vol.109
, pp. 182-186
-
-
Modesitt, S.C.1
Sill, M.2
Hoffman, J.S.3
Bender, D.P.4
-
12
-
-
34250651294
-
Histone deacetylase inhibitors of demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy
-
Piekarz RL, Sackett DL, Bates SE,. Histone deacetylase inhibitors of demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J. 2007; 13: 30-39.
-
(2007)
Cancer J.
, vol.13
, pp. 30-39
-
-
Piekarz, R.L.1
Sackett, D.L.2
Bates, S.E.3
-
13
-
-
33750530675
-
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
-
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzolez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006; 108: 3271-3279.
-
(2006)
Blood.
, vol.108
, pp. 3271-3279
-
-
Garcia-Manero, G.1
Kantarjian, H.M.2
Sanchez-Gonzolez, B.3
-
14
-
-
2542489234
-
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
-
DOI 10.1158/1078-0432.CCR-03-0409
-
Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical Cancer Res. 2004; 10: 3291-3300. (Pubitemid 38685433)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.10
, pp. 3291-3300
-
-
Lu, K.H.1
Patterson, A.P.2
Wang, L.3
Marquez, R.T.4
Atkinson, E.N.5
Baggerly, K.A.6
Ramoth, L.R.7
Rosen, D.G.8
Liu, J.9
Hellstrom, I.10
Smith, D.11
Hartmann, L.12
Fishman, D.13
Berchuck, A.14
Schmandt, R.15
Whitaker, R.16
Gershenson, D.M.17
Mills, G.B.18
Bast Jr., R.C.19
-
15
-
-
5144231704
-
WAF1/CIP1 and prolonged progression-free survival
-
DOI 10.1158/1078-0432.CCR-04-0698
-
Rosen DG, Wang L, Jain AJ, et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res. 2004; 10: 6559-6566. (Pubitemid 39346551)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.19
, pp. 6559-6566
-
-
Rosen, D.G.1
Wang, L.2
Jain, A.N.3
Lu, K.H.4
Luo, R.Z.5
Yu, Y.6
Liu, J.7
Bast Jr., R.C.8
-
16
-
-
41149093072
-
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation
-
DOI 10.1002/cncr.23323
-
Feng W, Marquez RT, Lu Z, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter mehtylation. Cancer. 2008; 112: 1489-1502. (Pubitemid 351441161)
-
(2008)
Cancer
, vol.112
, Issue.7
, pp. 1489-1502
-
-
Feng, W.1
Marquez, R.T.2
Lu, Z.3
Liu, J.4
Lu, K.H.5
Issa, J.-P.J.6
Fishman, D.M.7
Yu, Y.8
Bast Jr., R.C.9
-
17
-
-
33646411738
-
Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer
-
Lu Z, Luo RZ, Peng H, et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res. 2006; 12: 2404-2413.
-
(2006)
Clin Cancer Res.
, vol.12
, pp. 2404-2413
-
-
Lu, Z.1
Luo, R.Z.2
Peng, H.3
-
18
-
-
10744223629
-
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation
-
DOI 10.1093/hmg/ddg204
-
Fujii S, Luo RZ, Yuan J, et al. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet. 2003; 12: 1791-1800. (Pubitemid 36944134)
-
(2003)
Human Molecular Genetics
, vol.12
, Issue.15
, pp. 1791-1800
-
-
Fujii, S.1
Luo, R.Z.2
Yuan, J.3
Kadota, M.4
Oshimura, M.5
Dent, S.R.6
Kondo, Y.7
Issa, J.-P.J.8
Bast Jr., R.C.9
Yu, Y.10
-
19
-
-
57449121645
-
A Ras-related imprinted tumor suppressor gene ARHI regulates autophagy and tumor dormancy in ovarian cancer
-
Lu Z, Luo RZ, Lu Y, et al. A Ras-related imprinted tumor suppressor gene ARHI regulates autophagy and tumor dormancy in ovarian cancer. J Clin Invest. 2008; 118: 3917-3929.
-
(2008)
J Clin Invest.
, vol.118
, pp. 3917-3929
-
-
Lu, Z.1
Luo, R.Z.2
Lu, Y.3
-
20
-
-
12944308330
-
Eating oneself and uninvited guests: Autophagy-related pathways in cellular defense
-
DOI 10.1016/j.cell.2005.01.005, PII S0092867405000437
-
Levine B,. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell. 2005; 120: 159-162. (Pubitemid 40174758)
-
(2005)
Cell
, vol.120
, Issue.2
, pp. 159-162
-
-
Levine, B.1
-
21
-
-
22744459936
-
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells
-
DOI 10.1021/jm058214k
-
Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC,. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem. 2005; 48: 5047-5051. (Pubitemid 41033145)
-
(2005)
Journal of Medicinal Chemistry
, vol.48
, Issue.15
, pp. 5047-5051
-
-
Gediya, L.K.1
Chopra, P.2
Purushottamachar, P.3
Maheshwari, N.4
Njar, V.C.O.5
-
22
-
-
80052954245
-
-
Accessed on September 1, 2010
-
Lee JJ, Kong M, Ayers GD, Lotan R,. SYNERGY Software. Accessed on September 1, 2010.
-
SYNERGY Software
-
-
Lee, J.J.1
Kong, M.2
Ayers, G.D.3
Lotan, R.4
-
23
-
-
0002658306
-
The median-effect principle and the combination index for quantification of synergism and antagonism
-
Chou T.C. Rideout D.C. eds. San Diego, CA: Academic Press.
-
Chou TC,. The median-effect principle and the combination index for quantification of synergism and antagonism. In:, Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego, CA: Academic Press; 1991: 61-101.
-
(1991)
Synergism and Antagonism in Chemotherapy
, pp. 61-101
-
-
Chou, T.C.1
-
24
-
-
0013886333
-
Evaluation of survival data and 2 new rank order statistics arising in its consideration
-
Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemotherapy Rep. 1966; 50: 163-170.
-
(1966)
Cancer Chemotherapy Rep.
, vol.50
, pp. 163-170
-
-
Mantel, N.1
-
25
-
-
84950651862
-
The efficiency of Cox's likelihood function for censored data
-
Efron B,. The efficiency of Cox's likelihood function for censored data. JASA. 1977; 72: 557-565.
-
(1977)
JASA
, vol.72
, pp. 557-565
-
-
Efron, B.1
-
26
-
-
33748794547
-
Theoretical basis, experimental design, and computerized simulation and antagonism in drug combination studies
-
Chou TC,. Theoretical basis, experimental design, and computerized simulation and antagonism in drug combination studies. Pharmacol Rev. 2006; 58: 621-681.
-
(2006)
Pharmacol Rev.
, vol.58
, pp. 621-681
-
-
Chou, T.C.1
-
27
-
-
20344394418
-
Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
-
DOI 10.1016/j.leukres.2004.11.022, PII S014521260500038X
-
Yang H, Hoshino K, Sanchez-Gonzolez B, Kantarjian H, Garcia-Manero G,. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res. 2005; 29: 739-748. (Pubitemid 40779480)
-
(2005)
Leukemia Research
, vol.29
, Issue.7
, pp. 739-748
-
-
Yang, H.1
Hoshino, K.2
Sanchez-Gonzalez, B.3
Kantarjian, H.4
Garcia-Manero, G.5
-
28
-
-
33746679765
-
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells
-
DOI 10.1007/s00280-006-0225-6
-
Hurtubise A, Momparler RL,. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-aza-2′-deoxycytidine on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006; 58: 618-625. (Pubitemid 44167387)
-
(2006)
Cancer Chemotherapy and Pharmacology
, vol.58
, Issue.5
, pp. 618-625
-
-
Hurtubise, A.1
Momparler, R.L.2
-
29
-
-
34250661469
-
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies
-
Fandy TE, Carraway H, Gore SD,. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007; 13: 40-48.
-
(2007)
Cancer J.
, vol.13
, pp. 40-48
-
-
Fandy, T.E.1
Carraway, H.2
Gore, S.D.3
-
30
-
-
34248325147
-
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma
-
DOI 10.1002/cncr.22652
-
Venturelli S, Armeanu S, Pathil A, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer. 2007; 109: 2132-2141. (Pubitemid 46744210)
-
(2007)
Cancer
, vol.109
, Issue.10
, pp. 2132-2141
-
-
Venturelli, S.1
Armeanu, S.2
Pathil, A.3
Hsieh, C.-J.4
Weiss, T.S.5
Vonthein, R.6
Wehrmann, M.7
Gregor, M.8
Lauer, U.M.9
Bitzer, M.10
-
31
-
-
58749100626
-
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis
-
Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S,. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009; 200: 177.e1-177.e9.
-
(2009)
Am J Obstet Gynecol.
, vol.200
-
-
Li, Y.1
Hu, W.2
Shen, D.Y.3
Kavanagh, J.J.4
Fu, S.5
-
32
-
-
33847130464
-
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients [serial online
-
Sonnemann J, Gange J, Pitz S, et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients [serial online. BMC Cancer. 2006; 6: 183.
-
(2006)
BMC Cancer.
, vol.6
, pp. 183
-
-
Sonnemann, J.1
Gange, J.2
Pitz, S.3
-
33
-
-
70749118328
-
Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines
-
Dietrich CS, 3rd, Greenberg VL, DeSimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol. 2010; 116: 126-130.
-
(2010)
Gynecol Oncol.
, vol.116
, pp. 126-130
-
-
Dietrich III, C.S.1
Greenberg, V.L.2
Desimone, C.P.3
-
34
-
-
61749093379
-
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
-
Steele N, Finn P, Brown R, Plumb JA,. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer. 2009; 100: 758-763.
-
(2009)
Br J Cancer.
, vol.100
, pp. 758-763
-
-
Steele, N.1
Finn, P.2
Brown, R.3
Plumb, J.A.4
-
35
-
-
39749155114
-
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
-
DOI 10.1007/s00280-007-0531-7
-
Cashen AF, Shah AK, Todt L, Fisher N, DiPeriso J,. Pharmacokinetics of decitabine administered as a 3-hour infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol. 2008; 61: 759-766. (Pubitemid 351302031)
-
(2008)
Cancer Chemotherapy and Pharmacology
, vol.61
, Issue.5
, pp. 759-766
-
-
Cashen, A.F.1
Shah, A.K.2
Todt, L.3
Fisher, N.4
DiPersio, J.5
-
36
-
-
17444452612
-
Low-dose 5-Aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
-
Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18: 956-962. (Pubitemid 30123770)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.5
, pp. 956-962
-
-
Wijermans, P.1
Lubbert, M.2
Verhoef, G.3
Bosly, A.4
Ravoet, C.5
Andre, M.6
Ferrant, A.7
-
37
-
-
21244431605
-
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
-
DOI 10.1200/JCO.2005.11.981
-
Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005; 23: 3948-3956. (Pubitemid 46218698)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.17
, pp. 3948-3956
-
-
Issa, J.-P.F.1
Gharibyan, V.2
Cortes, J.3
Jelinek, J.4
Morris, G.5
Verstovsek, S.6
Talpaz, M.7
Garcia-Manero, G.8
Kantarjian, H.M.9
-
38
-
-
33847609658
-
Identification of candidate methylation-responsive genes in ovarian cancer [serial online
-
Menendez L, Walker D, Matyunia LV, et al. Identification of candidate methylation-responsive genes in ovarian cancer [serial online. Mol Cancer. 2007; 6: 10.
-
(2007)
Mol Cancer.
, vol.6
, pp. 10
-
-
Menendez, L.1
Walker, D.2
Matyunia, L.V.3
-
39
-
-
59449088943
-
Treatment of ovarian cancer cell lines with 5-aza-2 deoxycytidine up-regulates the expression of cancer-testis antigens and class i major histocompatibility complex-encoded molecules
-
Adair SJ, Hogan KT,. Treatment of ovarian cancer cell lines with 5-aza-2 deoxycytidine up-regulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. 2009; 58: 589-601.
-
(2009)
Cancer Immunol.
, vol.58
, pp. 589-601
-
-
Adair, S.J.1
Hogan, K.T.2
-
40
-
-
77956525903
-
Genomewide DNA methylation analysis reveals novel targets for drug development in mantel cell lymphoma
-
Leshchenko VV, Kuo P-Y, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantel cell lymphoma. Blood. 2010; 116: 1025-1034.
-
(2010)
Blood.
, vol.116
, pp. 1025-1034
-
-
Leshchenko, V.V.1
Kuo, P.-Y.2
Shaknovich, R.3
|